Rapid Micro Biosystems (NASDAQ:RPID) Stock Rating Cut to “Hold” at Lake Street Capital

Rapid Micro Biosystems (NASDAQ:RPID – Get Free Report) was downgraded by investment analysts at Lake Street Capital from a “buy” rating to a “hold” rating in a report issued on Monday, FinViz reports. They currently have a $0.75 price target on the stock. Lake Street Capital‘s price objective would suggest a potential upside of 1.35% from the stock’s current price.

Several other analysts have also recently commented on the company. JPMorgan Chase & Co. set a $0.75 target price on Rapid Micro Biosystems in a report on Tuesday. Weiss Ratings restated a “sell (d-)” rating on shares of Rapid Micro Biosystems in a research note on Thursday, October 15th. Finally, Roth Capital cut Rapid Micro Biosystems from a “buy” rating to a “neutral” rating and cut their price target for the company from $3.00 to $0.75 in a report on Tuesday. One investment analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Rapid Micro Biosystems presently has a consensus rating of “Hold” and an average price target of $1.81.

Get Our Latest Analysis on Rapid Micro Biosystems

Rapid Micro Biosystems Stock Up 13.7%

NASDAQ RPID opened at $0.74 on Monday. The stock’s 50 day simple moving average is $0.91 and its 200 day simple moving average is $2.06. Rapid Micro Biosystems has a one year low of $0.58 and a one year high of $4.94. The firm has a market cap of $37.12 million, a PE ratio of -0.66 and a beta of 1.52. The company has a debt-to-equity ratio of 1.08, a current ratio of 2.55 and a quick ratio of 1.51.

Rapid Micro Biosystems (NASDAQ:RPID – Get Free Report) last issued its quarterly earnings data on Monday, November 16th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.01). Rapid Micro Biosystems had a negative net margin of 145.56% and a negative return on equity of 177.04%. The business had revenue of $9.53 million during the quarter, compared to the consensus estimate of $9.85 million. As a group, sell-side analysts forecast that Rapid Micro Biosystems will post -0.94 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Rapid Micro Biosystems

Hedge funds and other institutional investors have recently made changes to their positions in the company. Pekin Hardy Strauss Inc. acquired a new stake in shares of Rapid Micro Biosystems in the 3rd quarter valued at $41,000. Temasek Holdings Private Ltd bought a new stake in shares of Rapid Micro Biosystems during the first quarter worth $50,000. Bank of America Corp DE lifted its stake in shares of Rapid Micro Biosystems by 139.9% during the first quarter. Bank of America Corp DE now owns 31,014 shares of the company’s stock valued at $70,000 after acquiring an additional 18,085 shares during the period. Dimensional Fund Advisors LP lifted its stake in shares of Rapid Micro Biosystems by 55.9% during the first quarter. Dimensional Fund Advisors LP now owns 87,589 shares of the company’s stock valued at $199,000 after acquiring an additional 31,407 shares during the period. Finally, Renaissance Technologies LLC boosted its holdings in Rapid Micro Biosystems by 9.5% in the first quarter. Renaissance Technologies LLC now owns 126,617 shares of the company’s stock valued at $287,000 after acquiring an additional 10,990 shares during the last quarter. 52.60% of the stock is owned by institutional investors and hedge funds.

Latest Rapid Micro Biosystems News

These are some of the RPID news items that stood out recently:

  • Positive Sentiment: Merck KGaA signed a definitive agreement to acquire all outstanding RPID shares for $0.75 each in cash. Merck said Rapid Micro’s Growth Direct platform would strengthen its pharmaceutical quality-control workflow offerings. Acquisition announcement
  • Neutral Sentiment: Law firms announced investigations into whether the $0.75 offer fairly values RPID and whether deal terms could limit competing offers. These are inquiries, not findings, but could add uncertainty around the transaction. Shareholder investigation report
  • Negative Sentiment: Third-quarter results were slightly below analyst expectations: RPID reported a $0.22-per-share loss versus estimates of $0.21, and revenue of $9.53 million versus estimates of $9.85 million. The company also filed a notification of late quarterly filing, adding a reporting concern. Third-quarter results Late filing report

Rapid Micro Biosystems Company Profile

(Get Free Report)

Rapid Micro Biosystems develops automated microbial detection systems for pharmaceutical, biotechnology and other life sciences manufacturers. Its products are designed to support quality-control testing by identifying and measuring microbial growth in manufacturing environments and products. The company’s Growth Direct platform combines laboratory instruments, consumables and software to automate microbial testing. Its applications include sterility testing, bioburden testing and environmental monitoring, helping manufacturers assess contamination during production.

Read More

Receive News & Ratings for Rapid Micro Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rapid Micro Biosystems and related companies with MarketBeat.com's FREE daily email newsletter.